These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29051812)

  • 1. Patients' perceptions on the usability of the SurePal™ self-injection device for Omnitrope
    Coutant R; Dupuis C; Pigeon P; Rebaud P
    Ther Adv Endocrinol Metab; 2017 Sep; 8(9):129-137. PubMed ID: 29051812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptance of a reusable self-injection device for recombinant human growth hormone: final data from a questionnaire-based, cross-sectional, international, multicenter, observational study in pediatric patients.
    Schnabel D; Partsch CJ; Houang M; Ehtisham S; Johnstone H; Zabransky M; Kiess W
    Med Devices (Auckl); 2016; 9():317-24. PubMed ID: 27660496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study.
    Partsch CJ; Schnabel D; Ehtisham S; Johnstone HC; Zabransky M; Kiess W
    Med Devices (Auckl); 2015; 8():389-93. PubMed ID: 26405430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study.
    Rapaport R; Saenger P; Schmidt H; Hasegawa Y; Colle M; Loche S; Marcantonio S; Bonfig W; Zabransky M; Lifshitz F
    Med Devices (Auckl); 2013; 6():141-6. PubMed ID: 24039458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment.
    Pfäffle R; Schwab KO; Marginean O; Walczak M; Szalecki M; Schuck E; Zabransky M; Zucchini S
    Ther Adv Endocrinol Metab; 2013 Feb; 4(1):3-11. PubMed ID: 23515245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of Omnitrope
    Backeljauw P; Kanumakala S; Loche S; Schwab KO; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
    Eur J Pediatr; 2022 Jun; 181(6):2367-2378. PubMed ID: 35275291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study.
    Iughetti L; Tornese G; Street ME; Napoli F; Giavoli C; Antoniazzi F; Stagi S; Luongo C; Azzolini S; Ragusa L; Bona G; Zecchino C; Aversa T; Persani L; Guazzarotti L; Zecchi E; Pietropoli A; Zucchini S
    Ital J Pediatr; 2016 Nov; 42(1):93. PubMed ID: 27809913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
    Loche S; Kanumakala S; Backeljauw P; Schwab KO; Lechuga-Sancho AM; Esmael A; Urosevic D; Boldea A; Zabransky M
    Drug Des Devel Ther; 2024; 18():667-684. PubMed ID: 38454934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population.
    Arosio M; Arnaldi G; Gasco V; Giavoli C; Puxeddu E; Vettor R; Ambrosio MR; Gallinari P; Zouater H; Fedeli P; Ferone D
    J Endocrinol Invest; 2021 Feb; 44(2):327-337. PubMed ID: 32507990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) for the treatment of adult patients with growth hormone deficiency.
    Beck-Peccoz P; Minuto F; Leal-Cerro A; Zabransky M; Stalla G
    Ther Adv Endocrinol Metab; 2012 Jun; 3(3):85-91. PubMed ID: 23148199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of Omnitrope
    Ferone D; Profka E; Gasco V; Ambrosio MR; Colao A; Di Somma C; Puxeddu E; Arnaldi G; Pagano C; Zecchi E; Pietropoli A; Beck-Peccoz P
    J Endocrinol Invest; 2017 Jun; 40(6):669-678. PubMed ID: 28161880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope
    Beck-Peccoz P; Höybye C; Murray RD; Simsek S; Zabransky M; Zouater H; Stalla G
    Ther Adv Endocrinol Metab; 2020; 11():2042018820943377. PubMed ID: 32973992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.
    Iughetti L; Antoniazzi F; Giavoli C; Bona G; Aversa T; Greggio NA; Guazzarotti L; Minelli R; Perrone L; Persani L; Pozzobon G; Ragusa L; Stagi S; Tornese G; Zecchino C; Gallinari P; Zouater H; Fedeli P; Zucchini S
    J Endocrinol Invest; 2021 Mar; 44(3):493-503. PubMed ID: 32557273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.
    Fuchs GS; Mikkelsen S; Knudsen TK; Kappelgaard AM
    Clin Ther; 2009 Dec; 31(12):2906-14. PubMed ID: 20110030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis.
    Pollock RF; Qian Y; Wisniewski T; Seitz L; Kappelgaard AM
    Med Devices (Auckl); 2013; 6():107-14. PubMed ID: 23946672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
    Rashid N; Saenger P; Wu YL; Woehling H; Frankel M; Lifshitz F; Muenzberg M; Rapaport R
    Biol Ther; 2014 Dec; 4(1-2):27-39. PubMed ID: 25096555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ease of use and preference for a new disposable self-injection pen compared with a reusable pen for administering recombinant human growth hormone: A multicenter, 2-month, single-arm, open-label clinical trial in patient-caregiver dyads.
    Hey-Hadavi J; Pleil A; Deeb LC; Fuqua JS; Silverman LA; Reiner B; Newfield R; Rajicic N; Wajnrajch MP; Cara JF
    Clin Ther; 2010 Nov; 32(12):2036-47. PubMed ID: 21118739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.
    Bozzola M; Colle M; Halldin-Stenlid M; Larroque S; Zignani M;
    BMC Endocr Disord; 2011 Feb; 11():4. PubMed ID: 21294891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
    Schwarz HP; Walczak M; Birkholz-Walerzak D; Szalecki M; Nanu M; Woehling H; Schuck E
    Adv Ther; 2016 Mar; 33(3):423-34. PubMed ID: 26886776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T; Saenger P; Peter F; Walczak M; Le Bouc Y; Khan-Boluki J; Berghout A
    Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.